ZTS
Status-Quo-PlayerZoetis
$120.08
+1.91%
as of 13 Apr
Power Core
The moat in one sentence: Zoetis's power derives from the compounding interaction between its direct-to-veterinarian sales network and a continuously refreshed product portfolio that creates switching costs at the point of prescribing, not at the point of chemistry.
Direction of Movement
Upward, Driven by Novel Biologics and Distribution Flywheel
ROC 200
-28.3%
ZTS
Zoetis
$120.08
+1.91%
as of 13 Apr
DCF Fair Value: $144.61
mOS zones are proprietary L17X overlays and do not constitute trading signals or investment advice.
Company Profile
Zoetis Inc. is a leading animal health company that engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. It operates across seven major product categories, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals, and animal health diagnostics. The company serves a diversified portfolio of species, encompassing livestock such as cattle, swine, poultry, fish, and sheep, as well as companion animals like dogs, cats, and horses. Zoetis Inc. holds the largest market share in the animal health industry, providing essential solutions for both production animals and pets worldwide. Its offerings support veterinarians, livestock producers, and pet owners by addressing key health needs in these sectors. Founded in 2013 and headquartered in Parsippany, New Jersey, Zoetis Inc. plays a pivotal role in advancing animal care through innovative products and services.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
14,500
Website
https://www.zoetis.com